Key terms
About PRFX
PainReform Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. It offers PRF-110, an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PRFX news
Apr 17
4:57pm ET
PainReform Ltd. Adjusts Warrant Terms
Apr 16
8:57am ET
PainReform Ltd. Launches $4 Million Public Offering
Apr 16
8:10am ET
PainReform prices 5M shares at 80c in public offering
Apr 09
9:27am ET
PainReform’s PRF-110 Sets New Pain Relief Benchmark
Apr 08
4:57pm ET
PainReform Shareholders Approve Key Proposals
Apr 03
11:15am ET
Buy Rating Affirmed for PainReform as PRF-110 Shows Promise in Non-Opioid Pain Management Market
Apr 02
9:28am ET
PainReform Hits 50% Enrollment Milestone
Apr 02
8:33am ET
PainReform reaches 50% enrollment in second part of Phase 3 trial of PRF-110
Mar 05
1:25pm ET
Buy Rating for PainReform’s PRF-110: Promising Non-Opioid Pain Solution Amidst Opioid Crisis
Mar 01
4:37pm ET
PainReform files to sell ordinary shares, no amount given
Mar 01
8:05am ET
PainReform reports 2023 EPS ($7.14) vs. ($8.13) last year
No recent press releases are available for PRFX
PRFX Financials
Key terms
Ad Feedback
PRFX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PRFX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
